PhaseII study of the efficacy of DOCETAXEL plus RAMUCIRUMAB for NSCLC with brain metastasis

Trial Profile

PhaseII study of the efficacy of DOCETAXEL plus RAMUCIRUMAB for NSCLC with brain metastasis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2018

At a glance

  • Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms RAMNITA
  • Most Recent Events

    • 01 Jun 2018 Trial design published in the Medicine.
    • 19 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 25 Apr 2017 Planned initiation date changed from 10 Jan 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top